The limitations of targeting MEK signalling in Glioblastoma therapy

Glioblastoma (GB) is a highly aggressive, difficult to treat brain tumour. Successful treatment, consisting of maximal safe tumour de-bulking, followed by radiotherapy and treatment with the alkylating agent Temozolomide (TMZ), can extend patient survival to approximately 15 months. Combination trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Selvasaravanan, Karthika D., Wiederspohn, Nicole, Hadzalic, Amina, Strobel, Hannah, Payer, Christel, Schuster, Andrea, Karpel-Massler, Georg, Siegelin, Markus D., Halatsch, Marc-Eric, Debatin, Klaus-Michael, Westhoff, Mike-Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198577/
https://www.ncbi.nlm.nih.gov/pubmed/32366879
http://dx.doi.org/10.1038/s41598-020-64289-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198577/
https://www.ncbi.nlm.nih.gov/pubmed/32366879
http://dx.doi.org/10.1038/s41598-020-64289-6

Ejemplares similares